Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome

BACKGROUND: Patients with autoimmune diseases were not evaluated in clinical trials with immune checkpoint inhibitors (ICIs), since a history of immune disorders, such as Guillain–Barré syndrome (GBS) and psoriasis, is one of the major risk factors for the development of immune-related adverse event...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Case Rep Oncol Med
Main Authors: Cortellini, Alessio, Parisi, Alessandro, Fargnoli, Maria Concetta, Cannita, Katia, Irelli, Azzurra, Porzio, Giampiero, Martinazzo, Claudio, Ficorella, Corrado
Formato: Artigo
Idioma:Inglês
Publicado: Hindawi 2018
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5863341/
https://ncbi.nlm.nih.gov/pubmed/29707397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/2783917
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares